TAK-272

DRUG3 trials

Sponsors

Takeda

Conditions

Hepatic ImpairmentJapanese Healthy Adult MalesRenal ImpairmentType 2 Diabetes Mellitus and Microalbuminuria

Phase 1

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

CompletedNCT02367872

TakedaHepatic Impairment, Renal Impairment

Start: 2015-03-31End: 2016-06-30Updated: 2017-11-06

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

CompletedNCT02370615

TakedaJapanese Healthy Adult Males

Start: 2015-02-28End: 2015-04-30Updated: 2016-05-23

Phase 2

A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

CompletedNCT02332824

TakedaType 2 Diabetes Mellitus and Microalbuminuria

Start: 2014-10-16End: 2016-08-18Updated: 2018-08-13

Related Papers

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Clinical Drug Investigation2018-09-07